• Latest News
  • KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 fo

    Stevenage, UK, 11 December 2018 - KaNDy Therapeutics, a clinical-stage company developing a potential breakthrough non-hormonal treatment for multiple debilitating symptoms of the menopause, today announces initiation of the Phase 2b clinical trial evaluating NT-814 in women with troublesome symptoms of the... read more


Funding Partners: